Project Grant R01DA059152
Award Date
8/1/23
Completion Date
7/31/26
Dollars Obligated
$3M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40526, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
This $6,439,263 federal Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 Drug Abuse and Addiction Research Programs) aims to determine the impact of maternal substance use on maternal immune activation, placental function, and offspring neurobehavioral development. The project will leverage the Healthy Brain and Child Development (HBCD) study to perform maternal immune profiling, placental and cord blood analysis, and novel neuroinflammation imaging on 400 pregnancies...
This $2,267,819 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Abuse and Addiction Research Programs) will fund research by the University of Washington to characterize extracellular vesicle (EV) profiles in healthy pregnancies and those complicated by opioid use disorder. The goal is to identify biomarkers in placental EVs and fetal brain/central nervous system EVs that could predict an infant's risk of developing neonatal opioid withdrawal syndrome (NOWS) and...
The National Institute on Drug Abuse (NIDA) awarded a Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) totaling $1,499,606.00 to the Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, with a project period from September 30, 2024 to July 31, 2029. The goal of this project is to characterize health outcomes from birth to 5 years of age in children born to individuals with opioid use disorder, identify disparities across populations,...
The National Institute on Drug Abuse (NIDA) awarded a $3,067,394 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation. The grant, titled "Engaging People Who Use Drugs in Harm Reduction Service Delivery: An Intravention to Reduce Risk of HIV, HCV, Overdose, and Injection-Related Infections in Rural Appalachia," will test a peer-driven approach to address unmet harm reduction needs in two rural Kentucky...
This Project Grant award of $135,906 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research on the impact of perinatal fentanyl exposure on the development of the mesolimbic dopamine pathway and associated behavioral outcomes. The research aims to use differential gene expression, morphological analysis, and fiber photometric recording to investigate how perinatal fentanyl exposure affects the structure and function...
This $284,040 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to conduct integrated single-cell and spatial mapping of the habenula circuitry to identify projection-specific molecular pathways associated with opioid exposure. The Lieber Institute for Brain Development in Baltimore, MD will lead this research effort from September 1, 2024 to August 31, 2026. The project will generate a...
This $585,975 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to discover and functionally characterize long non-coding RNAs (lncRNAs) in opioid use disorder (OUD) within the context of HIV at single-cell resolution. The University of Massachusetts Medical School will lead this 5-year effort to systematically identify novel lncRNAs in human and mouse brain tissues affected by OUD and HIV,...